T/t of tetanus
Reading File
Finding Sources
Searching PubMed
tetanus treatment management
Reading File
Reading File
Reading File
Reading File
Reading File
I now have excellent, comprehensive content from multiple authoritative sources. Let me compile the full answer.
Tetanus - Treatment (T/T)
Overview
Tetanus is a toxin-mediated disease caused by Clostridium tetani, a gram-positive, anaerobic, spore-forming bacillus. It produces tetanospasmin, which blocks inhibitory neurotransmitter (glycine/GABA) release at spinal interneurons, causing uncontrolled skeletal muscle spasms. Management requires four simultaneous strategies:
- Supportive care (control of spasms and autonomic dysfunction)
- Elimination/neutralization of unbound toxin
- Prevention of further toxin production
- Active immunization
1. Supportive Care
A. Control of Muscle Spasms
- Minimize stimulation - nurse in a quiet, darkened room; avoid unnecessary handling, noise, or light (reflex spasms triggered by any stimulus)
- Benzodiazepines - first-line and mainstay of therapy
- Diazepam - most extensively studied; 5 mg IV increments titrated to effect; rapid onset, wide safety margin; can be given orally/rectally/IV. Note: long half-life and active metabolites may cause prolonged sedation; IV formulation contains propylene glycol (risk of lactic acidosis at high doses)
- Lorazepam - equally effective
- Midazolam - short half-life, no propylene glycol, given as continuous infusion; preferred where available but cost-prohibitive in many regions
- Magnesium sulfate - effective adjuvant and emerging first-line for mild-to-moderate tetanus; controls spasms and muscle rigidity
- Dantrolene - direct muscle relaxant (no CNS activity); adjunctive agent to reduce need for mechanical ventilation
- Propofol infusion - effective but expensive
- Intrathecal baclofen - has been used but no advantage over benzodiazepines
Note: Neuroleptics and barbiturates offer no advantage over benzodiazepines.
B. Airway and Ventilation
- If spasms cannot be controlled or airway compromise develops: neuromuscular blockade + mechanical ventilation
- Succinylcholine should NOT be used as first-line NMB - risk of severe hyperkalemia from neuromuscular disease (onset ~4 days after disease onset)
- Preferred: Long-acting non-depolarizing agents (vecuronium 6-8 mg/hour, rocuronium) - shorter acting, fewer cardiovascular side effects
- Tracheostomy should be placed if the endotracheal tube itself triggers spasms
- Feeding tube for nutritional support (due to trismus and dysphagia)
C. Autonomic Dysfunction Management
Autonomic instability reflects excessive catecholamine release and is a major cause of death:
- Labetalol (0.25-1.0 mg/min IV) - first choice for hypertension/tachycardia (combined alpha + beta blockade)
- Morphine - useful for autonomic instability; reduces sympathetic discharge
- Hypotension - may require norepinephrine
- Bradycardia - may require temporary cardiac pacemaker
- Avoid pure beta-blockers (propranolol) - risk of unopposed alpha activity causing severe hypertension
2. Neutralization of Unbound Toxin (Passive Immunization)
- Human Tetanus Immunoglobulin (HTIG) - preferred agent
- Dose: 500-3000 IU IM (single dose) as soon as possible
- Bailey & Love recommends 250-500 U IM for contaminated wounds; Goldman-Cecil recommends 500 IU IM for established tetanus
- Neutralizes toxin that has NOT yet entered neurons (bound toxin cannot be reversed)
- Pooled IV immunoglobulin (IVIG) - alternative if HTIG unavailable
- Equine tetanus antitoxin (ATG/ATS) - alternative if human preparation unavailable, but higher risk of hypersensitivity reactions; test dose required
- Some centers use intrathecal HTIG to achieve higher CSF concentrations, but benefit remains debated
3. Prevention of Further Toxin Production
A. Antibiotics
- Metronidazole - drug of choice; 500 mg IV every 8 hours (or 2 g/day IV) for 7-10 days; kills vegetative C. tetani without the convulsant properties of penicillin
- Penicillin G (1-10 MU/day IV) - traditional alternative but has GABA-antagonist properties that may worsen spasms; metronidazole is preferred
- Alternatives: tetracyclines, erythromycin (for penicillin-allergic patients)
B. Wound Care
- Surgical debridement of the wound is mandatory - remove devitalized tissue, foreign material, pus
- Debridement should be performed after HTIG administration to prevent further toxin release into circulation during manipulation
- Wound excision may be required for heavily contaminated or cavitating wounds
4. Active Immunization
- Tetanus toxoid 0.5 mL IM - administered at a site separate from HTIG
- Having tetanus does NOT confer immunity (the amount of toxin sufficient to cause disease is sub-immunogenic)
- Initiate/complete the standard 3-dose primary series in unimmunized patients
- Boosters given at a separate site from passive immunization
Prophylaxis in Wounds (Summary Table)
| Wound Type | Immunization Status | Management |
|---|---|---|
| Clean, minor | <3 doses or unknown | Toxoid only |
| Clean, minor | ≥3 doses, last <10 years | Nothing |
| Clean, minor | ≥3 doses, last >10 years | Toxoid booster |
| Tetanus-prone (contaminated, deep, devitalized) | <3 doses or unknown | Toxoid + HTIG |
| Tetanus-prone | ≥3 doses, last <5 years | Nothing |
| Tetanus-prone | ≥3 doses, last >5 years | Toxoid booster |
Clinical Grades (Ablett Classification)
| Grade | Features |
|---|---|
| I (Mild) | Mild-moderate trismus; no spasms; no respiratory compromise |
| II (Moderate) | Moderate trismus; spasms; mild respiratory involvement |
| III (Severe) | Severe trismus; spontaneous spasms; respiratory compromise; autonomic instability |
| IV (Very Severe) | Grade III + severe autonomic instability |
Monitoring and Prognosis
- ICU admission mandatory for all but very mild cases
- Overall case fatality rate ~18%; rises to ~50% in patients >70 years
- Recovery depends on growth of new axon terminals (toxin binding is irreversible)
- Wean benzodiazepines slowly over at least 2 weeks to prevent withdrawal
Sources:
- Rosen's Emergency Medicine, Chapter 118 (pp. 2589-2592)
- Goldman-Cecil Medicine, Chapter on Tetanus (pp. 3059-3060)
- Bailey & Love's Short Practice of Surgery 28th Ed., p. 476
Recent literature: A 2025 Lancet Infectious Diseases review (PMID 40543524) covers updated recognition and management; no major changes to the core treatment framework above have been identified.
Inj. Robinaux?
Finding Sources
Searching the Web
Injection Robinul glycopyrrolate tetanus autonomic instability use dose
Finding Sources
Searching the Web
glycopyrrolate Robinul tetanus autonomic dysfunction hypersalivation role bradycardia
Injection Robinul (Glycopyrrolate)
Robinul is the brand name for glycopyrrolate, a synthetic quaternary ammonium anticholinergic (antimuscarinic) agent.
Drug Class & Mechanism
- Quaternary ammonium compound - does NOT cross the blood-brain barrier (unlike atropine), so it has minimal CNS effects
- Competitively blocks muscarinic acetylcholine receptors at postganglionic cholinergic nerve endings
- Acts on smooth muscle, cardiac muscle, sinoatrial node, AV node, and exocrine glands
Role in Tetanus
In tetanus, glycopyrrolate is used specifically for autonomic instability, particularly the parasympathetic surges:
- Controls excessive secretions - hypersalivation, bronchorrhoea, tracheobronchial secretions (very relevant in tetanus where patients have trismus and cannot swallow)
- Bradycardia - blocks vagal overactivity causing episodic bradycardia in tetanus autonomic storms
- Bronchospasm - anticholinergic bronchodilation
- Preferred over atropine in this setting because it does not cause central excitation or cross the blood-brain barrier, making it safer in a patient already prone to spasms
Formulation & Doses
| Preparation | Details |
|---|---|
| Injection | 0.2 mg/mL solution (1 mL, 2 mL, 5 mL, 20 mL vials) |
| Tablets | 1 mg, 2 mg |
Dosing:
| Indication | Dose |
|---|---|
| Preanesthetic / antisialogogue | 0.004-0.01 mg/kg IM, 30-60 min before; max 0.2-0.3 mg in adults |
| Intraoperative bradycardia / vagal reflex | 0.1 mg IV; repeat at 2-3 min intervals as needed |
| Reversal of NMB (with neostigmine) | 0.2 mg IV per 1 mg neostigmine (or per 5 mg pyridostigmine) |
| Peptic ulcer adjunct | 0.1-0.2 mg IM/IV every 4 hours (3-4x/day) |
Pharmacokinetics
| Route | Onset | Peak | Duration |
|---|---|---|---|
| IV | ~1 min | - | 3-7 hours |
| IM/SC | 15-30 min | 30-45 min | 3-7 hours |
| Oral | Variable | ~5 hours | 8-12 hours |
Key Advantages Over Atropine
- Does not cross the blood-brain barrier - no CNS stimulation or confusion
- Longer duration of action (3-7 hours vs. atropine's 1-2 hours)
- More potent antisialogogue effect (less tachycardia at antisialogogue doses)
- Onset and offset similar to neostigmine - better cardiac matching when reversing NMB
- Pregnancy risk category B
Contraindications
- Angle-closure glaucoma
- Obstructive uropathy / urinary retention
- Paralytic ileus / GI obstruction
- Myasthenia gravis
- Unstable cardiovascular status
- Toxic megacolon / severe ulcerative colitis
Side Effects
- Dry mouth, decreased secretions
- Tachycardia (less than atropine)
- Urinary retention
- Constipation / reduced GI motility
- Blurred vision (less than atropine - minimal cycloplegia at standard doses)
- Heat stroke risk (impaired sweating)
- No CNS effects (no confusion, no central excitation) - advantage over atropine
In the context of tetanus, it is a useful adjunct alongside labetalol and morphine for managing the autonomic instability component, particularly for controlling secretions in a patient who cannot swallow and for managing vagally-mediated bradycardia.
Carbanul
This is a shared conversation. Sign in to Orris to start your own chat.